Merck sues to stop Medicare drug price negotiations; doctors delay lifesaving therapies due to cancer drug shortages; a federal appeals court will hear Affordable Care Act coverage prevention case.
Merck Sues US Government Over Medicare Drug Price Negotiations
On Tuesday, Merck & Co filed a lawsuit against the US government seeking to block a drug price negotiation program included in the Inflation Reduction Act, according to Reuters. The company argued that the program violates the Fifth and First Amendments of the US Constitution and marks the first challenge by a drugmaker to the law. Merck stated it plans to take this case all the way to the Supreme Court if necessary.
Cancer Drug Shortages Reach a New Record-High
A severe shortage of effective chemotherapy drugs is ultimately putting at risk the lives of patients with cancer, according to The Washington Post. The shortage, exacerbated by low profit margins on generic drugs and an overreliance on foreign manufacturing, is affecting a wide range of cancer treatments, including pediatric cases. Furthermore, delays in treatment caused by the shortage may have devastating consequences, with studies showing increased sickness or mortality rates for common cancers when treatment is delayed.
Appeals Court to Hear Texas Case Against ACA Provision Mandate
A federal appeals court is considering whether to continue the temporary pause of a Texas district court's ruling that invalidated an Affordable Care Act provision mandating insurers to cover preventive services for free, according to The Hill. The pause allows HHS to continue requiring insurance companies to cover preventive services such as HIV prevention drugs and cancer screenings without cost-sharing. The case was brought forward by conservative Texas employers and individuals, who believe the provision violates their religious beliefs.
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Integrated CKD Care Model Cuts ED Visits by 30%, Boosts Specialized Treatment
April 21st 2025An analysis of an interdisciplinary care model for managing chronic kidney disease (CKD) shows hospital admissions dropped by 26% and emergency department (ED) visits decreased by 30% after clinic initiation.
Read More